This funding will be used to launch a serial of non-invasive endometriosis tests and advance two innovative (non-hormonal and non-antibiotic) therapeutic programs for endometriosis and bacterial vaginosis. The company is also actively seeking global or regional partnerships for other Women's Health indications. Institutional investors such as Pivotal bioVenture Partners China, Sinovation Ventures, Emerging Technology Partners, and Triwise Capital participated in this round.

Heranova Lifesciences is a biotech company solely focused on developing integrated care solutions for Women's Health. Their goal is to address unmet needs in women's healthcare by offering internally developed and externally partnered diagnostics, drugs, and devices. The company was founded in 2022 by a team of serial entrepreneurs and seasoned MNC executives with support from a world-class Scientific Advisory Board. Heranova has already established presences in the United States and Asia.